Czechia· CZ-0286209
LYNOZYFIC
A linvoseltamab product containing linvoseltamab, registered in Czechia by Regeneron Ireland Designated Activity Company, Dublin. The same ATC class is registered in 3 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Linvoseltamab is registered in 3 of 19 countries.
Countries holding a registration under ATC L01FX37 (linvoseltamab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 2 of them publish a price we can compare per daily dose
Linvoseltamab · ATC L01FX37
3 / 19 countries
- Czechiaprice
- Denmark
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- LINVOSELTAMAB
- Manufacturer
- Regeneron Ireland Designated Activity Company, Dublin
- Country
- Czechia (CZ)
- ATC code
- L01FX37
- ATC class
- Linvoseltamab
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linvoseltamab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLynozyfic 200 mgRegeneron Ireland Designated Activity Company (DAC)
- FinlandLYNOZYFICRegeneron Ireland Designated Activity Company (DAC)
- IrelandLYNOZYFIC 200 mg concentrate for solution for infusionRegeneron Ireland Designated Activity Company
- IcelandLynozyficRegeneron Ireland Designated Activity Company
- SwedenLYNOZYFIC 200 mg Koncentrat till infusionsvätska, lösningRegeneron Ireland Designated Activity Company
- United StatesLYNOZYFICRegeneron Pharmaceuticals, Inc.
- SpainLYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- NetherlandsLYNOZYFIC 200 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lynozyfic
- Liechtenstein · Lynozyfic
- Norway · Lynozyfic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7eac01af-e4f3-47e7-87ab-720ed67981c3 GET /v1/drugs/7eac01af-e4f3-47e7-87ab-720ed67981c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF CNC SOL",
"source": "sukl",
"strength": "200MG",
"pack_size": "1X10ML",
"substance": "LINVOSELTAMAB",
"cz_kod_sukl": "0286209",
"product_type": "BT",
"substance_codes": "1719",
"registration_state": "R",
"registration_number": "EU/1/25/1917/002"
}See everything about linvoseltamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.